Fluorescence in situ hybridization (FISH) remains a gold standard for assessing gene amplification and deletion in clinical and translational oncology. Accurate evaluation of targets such as HER2 is critical for patient stratification, therapeutic response prediction, and inclusion in immunotherapy clinical trials. Discovery Life Sciences (Discovery) leverages CAP/CLIA certified FISH services with deep expertise in assay design and analysis to support biopharma partners advancing precision oncology programs.
